secwatch.observer — SEC 8-K summary
======================================

Issuer:     CTI BIOPHARMA CORP (—)
CIK:        0000891293
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001193125-23-140076
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CTI BioPharma to be acquired by Sobi for $9.10 per share in cash
----------------------------------------------------------------

- Offer price of $9.10 per share in cash through a tender offer and subsequent merger.
- Minimum condition requires tender of shares representing >50% of outstanding plus certain convertible securities.
- CTI must pay Sobi a $59 million termination fee if it accepts a superior offer.
- Stockholders representing 6.7% of shares entered into a support agreement to tender their shares.
- Board amended bylaws to add exclusive forum provision for Delaware Chancery Court.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/891293/000119312523140076/0001193125-23-140076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/891293/000119312523140076/d436727d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-140076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer